BIOTELEMETRY, INC.
heartbeam.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2020 10-Q, filed Oct 29, 2020. Its latest SEC filing is a SC 13G/A from Mar 10, 2021.
10-Q for Q3 FY2020, filed Oct 29, 2020
The sections below describe the company as of the FY2019 annual report.
What Did They Do?
Provides remote cardiac monitoring services for physicians, core-laboratory services for drug and medical-device trials, and monitoring devices for healthcare providers.
10-K for FY2019, filed Feb 28, 2020The Healthcare segment, which generated 85% of our revenue in 2019, is focused on remote cardiac monitoring to identify cardiac arrhythmias…View ↗
The Research segment, or BioTel Research™, is engaged in centralized core laboratory services providing cardiac monitoring, imaging…View ↗
The Corporate and Other category contains our other operating business brands: BioTel Alliance™, which focuses on manufacturing, testing…View ↗
Who Were Their Customers?
A direct sales force markets cardiac monitoring to cardiologists, electrophysiologists, neurologists and primary care physicians. Clinical-trial services are marketed to pharmaceutical and medical-device companies, contract research organizations and academic research organizations; manufactured products go to physicians, hospitals and other cardiac-monitoring providers.
10-K for FY2019, filed Feb 28, 2020We market our cardiac monitoring solutions in our Healthcare segment through our direct sales force primarily to cardiologists…View ↗
We market our Research segment services to pharmaceutical companies, medical device companies, CROs and academic research organizations. We…View ↗
Our BioTel Alliance™ brand, currently included in the Corporate and Other category, markets our manufactured products to physicians…View ↗
How Were They Changing?
-
Feb 9, 2021
Philips completed its acquisition of BioTelemetry
BioTelemetry became a wholly owned Philips subsidiary after the tender offer and merger.
Sources
8-K, filed Feb 9, 2021
The Offer expired at 12:00 midnight, New York time, on February 9, 2021 (the “Expiration Time”), (one minute after 11:59 p.m., New York…View ↗
-
Oct 29, 2020
CEO forecast over 15% top-line growth
The forecast applied to 2021.
Sources
8-K, filed Oct 29, 2020
“Despite the numerous challenges posed by the pandemic, we remained focused on executing our strategy. We continued to augment our…View ↗
A shared implantable-device workflow
The earlier report describes pacemaker monitoring; the latest adds Geneva's platform, which brings data from several manufacturers' implantable devices into one workflow alongside monitoring services.
10-K for FY2016, filed Feb 22, 2017 10-K for FY2019, filed Feb 28, 2020The Healthcare segment, operating as CardioNet, LLC ("CardioNet") and Heartcare Corporation of America, Inc. ("Heartcare"), is focused on…View ↗
Our Geneva platform is a cloud-based solution for point of care and remote monitoring data that consolidates and manages information from…View ↗
Broader digital population-health services
The earlier report describes a wireless blood-glucose meter and cloud analytics; the latest also describes a diabetes-management platform and contracted service relationships.
10-K for FY2016, filed Feb 22, 2017 10-K for FY2019, filed Feb 28, 2020In addition, in December 2016, we acquired Telcare, the first company to receive FDA clearance for a cellular-enabled BGM system. This…View ↗
Loading...
